The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

References

• CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for Diagnosis, Management and Prevention of COPD. Updated 2009Gig Harbor, WAMedical Communications Resources, Inc2009http://www.goldcopd.com
   Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCBhowmikAJeffriesDJWedzichaJATime course and recovery of exacerbations in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200016151608161310806163
   PubMed Web of Science ®Google Scholar
• BourbeauJFordGZackonHPinskyNLeeJRubertoGImpact on patients’ health status following early identification of a COPD exacerbationEur Respir J200730590791317715163
   PubMed Web of Science ®Google Scholar
• MiravitllesMFerrerMPontAEffect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax200459538739515115864
   PubMed Web of Science ®Google Scholar
• NishimuraKSatoSTsukinoMEffect of exacerbations on health status in subjects with chronic obstructive pulmonary diseaseHealth Qual Life Outcomes200976919624834
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• SpencerSCalverleyPMBurgePSJonesPWImpact of preventing exacerbations on health status in chronic obstructive pulmonary diseaseEur Respir J200423569870215176682
   PubMed Web of Science ®Google Scholar
• DonaldsonGCWedzichaJACOPD exacerbations: 1: epidemiologyThorax200661216416816443707
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJMartinez-GarciaMARoman-SanchezPRSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• BurgeSWedzichaJACOPD exacerbations: definitions and classificationsEur Respir J200321Suppl 4146s53s
   Web of Science ®Google Scholar
• SethiSEvansNGrantBJMurphyTFNew strains of bacteria and exacerbations in chronic obstructive pulmonary diseaseN Engl J Med2002347746547112181400
   PubMed Web of Science ®Google Scholar
• SethiSSethiREschbergerKAirway bacterial concentrations and exacerbations of chronic obstructive pulmonary diseaseAm J Crit Clin Care Med20071764356361
   PubMed Web of Science ®Google Scholar
• BaathornEKerstjensHPostmaDTimensWMacNeeWAirways inflammation and treatment during acute exacerbations of COPDInt J Chron Obstruct Pulmon Dis20083221722918686731
   PubMedGoogle Scholar
• DonaldsonGCSeemungalTAPatelISLongitudinal changes in nature, severity and frequency of COPD exacerbationsEur Respir J200322693193614680081
   PubMed Web of Science ®Google Scholar
• HurstJRDonaldsonGCQuintTKBoldringJJBaghai-RavaryRWedzichaJATemporal clustering of exacerbations in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009179536937419074596
   PubMed Web of Science ®Google Scholar
• SorianoJBKiriVAPrideNBVestboJInhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patientsAm J Respir Med200321677414720023
   PubMedGoogle Scholar
• BahadoriKFitzGeraldJMLevyRDFeraTSwistonJRisk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalizationsCan Respir J2008164e43e4919707601
   PubMedGoogle Scholar
• LeffBBurtonLMaderSLHospital at home: feasibility and outcomes of a program to provide hospital-level care at home for acutely ill older patientsAnn Int Med20051431179880816330791
   PubMed Web of Science ®Google Scholar
• ColeCSWilliamsEBWilliamsRDAssessment and discharge planning for hospitalized older adults with deliriumMedsurg Nurs2006152717616700244
   PubMedGoogle Scholar
• Gruffydd-JonesKA national strategy for the management of chronic obstructive pulmonary disease in England: aiming to improve the quality of care for patientsPrim Care Respir J200817Suppl 1S1S819137200
   PubMedGoogle Scholar
• StrasselsSASmithDHSullivanSDMahajanPSThe costs of treating COPD in the United StatesChest2001119234435211171708
   PubMed Web of Science ®Google Scholar
• NiewoehnerDEThe impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary diseaseAm J Med200611910 Suppl 1384516996898
   PubMed Web of Science ®Google Scholar
• StanfordRHShenYMcLaughlinTCost of chronic obstructive pulmonary disease in the emergency department and hospitalTreat Respir Med20065534334916928147
   PubMedGoogle Scholar
• BlanchetteCMBroderMOryCChangeEAkazawaMDalalAACost and utilization of COPD and asthma among insured adults in the USCurr Med Res Opin2009251385139219419342
   PubMed Web of Science ®Google Scholar
• ShayaFTDongyiDAkazawaMOBurden of concomitant asthma and COPD in a Medicaid populationChest20081341141918339789
   PubMed Web of Science ®Google Scholar
• Simoni-WastiliLBlanchetteCMQianJBurden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilitiesAm J Ger Pharmacother200975262270
   Google Scholar
• ReisALBauldoffGSCasaburiRMahlerDARochesterCLHerreriasCPulmonary rehabilitation. Joint ACCP/AACVR evidence-based clinical practice guidelinesChest200713154S42S17494825
   PubMed Web of Science ®Google Scholar
• SundararajanLBalamiJPackhamSEffectiveness of outpatient pulmonary rehabilitation in elderly patients with chronic obstructive pulmonary diseaseJ Cardiopulm Rehabil Prev20091125, doi: 101097/HCR0b013e3181be7c56 [epub ahead of print].
   Web of Science ®Google Scholar
• AnthonisenNRConnettJEKileyJPEffects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health StudyJAMA199427219149715057966841
   PubMed Web of Science ®Google Scholar
• WilkinsonTMADonaldsonGCHurstJRSeemungalTARWedzichaJAEarly therapy improves outcomes of exacerbations of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2004169121298130314990395
   PubMed Web of Science ®Google Scholar
• BroedersMSanchisJLevyMLCromptonGKDekhuijzenPNfor the ADMIT Working GroupThe ADMIT series – issues in inhalation therapy. 2) improving technique and clinical effectivenessPrim Care Respir J2009182768219475324
   PubMedGoogle Scholar
• HananiaNAThe impact of inhaled corticosteroid and long-acting B-agonist combination therapy on outcomes in COPDPulm Pharmacol Ther200821354055018280761
   PubMed Web of Science ®Google Scholar
• KeatingGMMcCormackPLSalmeterol/fluticasone propionate. A review of its use in the treatment of chronic obstructive pulmonary diseaseDrugs200767162383240517983257
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus Inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• Di MarcoFMilic-EmiliJBoveriBEffect of inhaled broncho-dilators on inspiratory capacity and dyspnoea at rest in COPDEur Respir J2003211869412570114
   PubMed Web of Science ®Google Scholar
• CalverleyPMAReducing the frequency and severity of exacerbations of chronic obstructive pulmonary diseaseProc Am Thorac Soc20041212112416113424
   PubMedGoogle Scholar
• OakleyRHCidlowskiJAHomologous down regulation of the glucocorticoid receptor: the molecular machineryCrit Rev Eukaryot Gene Expr19933263888324294
   PubMedGoogle Scholar
• ChungKFCaramoriGAdcockIMInhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and futureEur J Clin Pharmacol200965985386119557399
   PubMed Web of Science ®Google Scholar
• BarnesNCQiuY-SPavordIDAnti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2006173773674316424444
   PubMed Web of Science ®Google Scholar
• KardosPWenchkerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007175214414917053207
   PubMed Web of Science ®Google Scholar
• HattotuwaKLGizyckiMJAnsariTWJefferyPKBarnesNCThe effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary diseaseAm J Resp Crit Care Med2002165121592159612070058
   PubMed Web of Science ®Google Scholar
• GizyckiMJHattotuwaKLBarnesNJefferyPKEffects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissueThorax200257979980312200525
   PubMed Web of Science ®Google Scholar
• ConfalonieriMMainardiEDella PortaRInhaled corticosteroids reduce neutrophilic inflammation in patients with chronic obstructive pulmonary diseaseThorax19985375835859797758
   PubMed Web of Science ®Google Scholar
• SinDDLacyPYorkPManSFPEffects of fluticasone on systemic markers of inflammationAm J Respir Crit Care Med20041707160165
   Web of Science ®Google Scholar
• Dal NegroRWPomariCTognellaSMichelettoCSalmeterol and fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophyllinePulm Pharmacol Ther200316424124612850128
   PubMed Web of Science ®Google Scholar
• EdwardsMJohnsonMJohnsonSSynergistic effects of salmeterol and fluticasone in human rhinovirus induced pro-inflammatory cytokine production [abstract]Am J Respir Crit Care Med2003167A399
   Google Scholar
• SeetoLJBurgessJKJohnsonPRBlackJLRothMLimSEffect of fluticasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD) [abstract]Am J Respir Crit Care Med2003167A318
   Google Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized clinical trial [Erratum in: Lancet. 2003;351(9369);1660]Lancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• LapperreTSSnoeck-StrobandJBGosmanMMEthe GLU-COLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study GroupEffect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary diseaseAnn Int Med2009151851752719841453
   PubMed Web of Science ®Google Scholar
• CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH StudyAm J Respir Crit Care Med2008178432232318676961
   PubMed Web of Science ®Google Scholar
• WoutersEFPostmaDSFokkensBfor the COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study GroupWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
   PubMed Web of Science ®Google Scholar
• AlsaeediASinDDMcAlisterFAThe effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trialsAm J Med20021131596512106623
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med343261902190911136260
   PubMed Web of Science ®Google Scholar
• PaggiaroPLDahleRBakranIFrithLHollingsworthKEfthimiouJMulticenter randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. [Erratum in: Lancet. 1998;351(9120):1968]Lancet199835191057737809519948
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Resp J20032157481
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH studyResp Res20091059
   PubMed Web of Science ®Google Scholar
• YoungJUnderstanding statistical analysis in the surgical literature: some key conceptsANZJ Surg2009795398403
   Web of Science ®Google Scholar
• SinDDWuLAndersonJAInhaled corticosteroids and mortality in chronic obstructive pulmonary diseaseThorax2005601299299716227327
   PubMed Web of Science ®Google Scholar
• MapelDWHurleyJSRoblinDSurvival of COPD patients using inhaled corticosteroids and long-acting beta agonistsRespir Med2006100459560916199151
   PubMed Web of Science ®Google Scholar
• MapelDWNelsonLSLydickESorianoJYoodMUDavisKJSurvival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators aloneCOPD20074212713417530506
   PubMedGoogle Scholar
• SinDDTuJVInhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164458058411520719
   PubMed Web of Science ®Google Scholar
• SorianoJBVestboJPrideNBKiriVMadenCMaierWCSurvival in COPD patients after regular use of fluticasone propionate and salmeterol in general practiceEur Respir J200220481982512412670
   PubMed Web of Science ®Google Scholar
• FanVSBrysonCLCurtisJRInhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysisAm J Respir Crit Care Med2003168121488149414525798
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLClinchJJMeasurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbationChest2002121368869611888946
   PubMed Web of Science ®Google Scholar
• ZhengJPYangLWuYMThe efficacy and safety of combination salmeterol (50 μg)/fluticasone propionate (500 μg) inhalation twice daily via Accuhaler in Chinese patients with COPDChest200713261756176317951625
   PubMed Web of Science ®Google Scholar
• RascatiKLAkazawaMJohnsrudMStanfordRHBlanchetteCMComparison of hospitalizations, emergency department visits, and the associated costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimenClin Ther20072961203121317692734
   PubMed Web of Science ®Google Scholar
• KiriVABettoncelliGTestiRViegiGInhaled corticosteroids are more effective in COPD patients when used with LABA than with SABARespir Med20059991115112415921904
   PubMed Web of Science ®Google Scholar
• AnzuetoAMcLaughlinTStanfordRHInitial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary diseaseCOPD20041220521417136988
   PubMedGoogle Scholar
• AkazawaMHayflingerDCStanfordRHBlanchetteCMEconomic assessment of initial maintenance therapy for chronic obstructive pulmonary disease from a managed care perspectiveAm J Managed Care20081472132
   Web of Science ®Google Scholar
• BlanchetteCMAkazawaMDalalASimoni-WastilaLRisk of hopitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adultsAm J Geriatr Pharmacother20086313814618775388
   PubMedGoogle Scholar
• DeleaTEHagiwaraMDalalAAStanfordRHBlanchetteCMHealthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapiesCurr Med Res Opin200935111319210134
   PubMed Web of Science ®Google Scholar
• Advair DISKUS [package insert]Research Triangle Park, NCGlaxo-SmithKline42009
   Google Scholar
• FergusonGTCalverleyPMAndersonJAPrevalence and progression of osteoporosis in patients with COPD. Results from TORCHChest200913661456146519581353
   PubMed Web of Science ®Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination. TORCH study resultsEur Resp J2009343641647
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAfor the INSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• SinDDTashkinDZhangXBudesonide and the risk of pneumonia: a meta-analysis of individual patient dataLancet2009374969171271919716963
   PubMed Web of Science ®Google Scholar
• HolguinFFolchEReddSCManninoDMComorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001Chest200512842005201116236848
   PubMed Web of Science ®Google Scholar
• TanSLWoodAMChronic obstructive pulmonary disease and comorbidity: a review and consideration of pathophysiologyPanminerva Med2009512819319776710
   PubMed Web of Science ®Google Scholar
• WeekesCEEmeryPWEliaMDietary counselling and food fortification in stable COPD: a randomised trialThorax200964432633119074931
   PubMed Web of Science ®Google Scholar
• PlanasMAlvarezJGarcia-PerisPANutritional support and quality of life in stable chronic obstructive pulmonary disease (COPD) patientsClin Nutr200524343344115896431
   PubMed Web of Science ®Google Scholar
• BarrRGCelliBRManninoDMComorbidities, patient knowledge, and disease management in a national sample of patients with COPDAm J Med2009122434835519332230
   PubMed Web of Science ®Google Scholar
• CoventryPADoes pulmonary rehabilitation reduce anxiety and depression in chronic obstructive pulmonary disease?Curr Opin Pulm Med200915214314919532030
   PubMed Web of Science ®Google Scholar
• OmachiTAKatzPPYelinEHDepression and health-related quality of life in chronic obstructive pulmonary diseaseAm J Med20091228778.e9e1519635280
   PubMed Web of Science ®Google Scholar
• SchneiderCJickSSBothnerUMeierCRChronic obstructive pulmonary disease and the risk of depressionChest2009103;doi: 101378/chest09-0614 [Epub ahead of print].
   Google Scholar
• FaulJLWilsonSRChuJWCanfieldJKuschnerWGThe effects of an inhaled corticosteroid on glucose control in type 2 diabetesClin Med Res200971–2142019251584
   PubMedGoogle Scholar
• VestboJAndersonJACalverleyPAdherence to inhaled therapy, mortality, and hospital admission in COPDThorax2009641193994319703830
   PubMed Web of Science ®Google Scholar
• CramerJABradley-KennedyCScaleraATreatment persistence and compliance with medications for chronic obstructive pulmonary diseaseCan Respir J2007141252917315055
   PubMed Web of Science ®Google Scholar
• RestrepoRDAlvarezMTWittnebelLDMedication adherence issues in patients treated for COPDInt J Chron Obstruct Pulm Dis200833371384
   PubMedGoogle Scholar
• BrocklebankDRamFComparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literatureHealth Tech Assess20015261149
   PubMedGoogle Scholar
• CazzolaMHananiaNAThe role of combination therapy with corticosteroids and long-acting beta-2-agonists in the prevention of exacerbations in COPDInt J Chron Obstruct Pulmon Dis20061434535418044091
   PubMedGoogle Scholar
• YawnBPKeenanJMCOPD – the primary care perspective: addressing epidemiology, pathology, diagnosis, treatment of smoking’s multiple morbidities and the patient’s perspectiveCOPD200741678317364679
   PubMedGoogle Scholar
• PriceDBTinkelmanDGNordykeRJIsonakaSHalbertRJCOPD Questionnaire Study GroupScoring system and clinical application of COPD diagnostic questionnairesChest200612961531153916778271
   PubMed Web of Science ®Google Scholar
• HernandezPBalterMBourbeauJHodderRLiving with chronic obstructive pulmonary disease: a survey of patients’ knowledge and attitudesRespir Med200910371004101219269150
   PubMed Web of Science ®Google Scholar